These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32818917)

  • 21. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability.
    Jha MK; Williamson DJ; Magharehabed G; Turkoz I; Daly EJ; Trivedi MH
    J Affect Disord; 2023 Jan; 321():153-160. PubMed ID: 36273682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Esketamine: a glimmer of hope in treatment-resistant depression.
    Kaur U; Pathak BK; Singh A; Chakrabarti SS
    Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):417-429. PubMed ID: 31745646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
    Ng J; Rosenblat JD; Lui LMW; Teopiz KM; Lee Y; Lipsitz O; Mansur RB; Rodrigues NB; Nasri F; Gill H; Cha DS; Subramaniapillai M; Ho RC; Cao B; McIntyre RS
    J Affect Disord; 2021 Oct; 293():285-294. PubMed ID: 34225208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Esketamine Nasal Spray for Treatment-Resistant Depression.
    Fantasia HC
    Nurs Womens Health; 2020 Jun; 24(3):228-232. PubMed ID: 32387141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study.
    d'Andrea G; Miuli A; Pettorruso M; Cavallotto C; Marrangone C; Cocco A; De Filippis S; Martiadis V; Andriola I; Barlati S; Vita A; Dell'Osso BM; Sensi SL; Di Lorenzo G; Martinotti G
    J Affect Disord; 2024 Dec; 367():583-588. PubMed ID: 39233241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression.
    Turkoz I; Alphs L; Singh J; Jamieson C; Daly E; Shawi M; Sheehan JJ; Trivedi MH; Rush AJ
    Acta Psychiatr Scand; 2021 Mar; 143(3):253-263. PubMed ID: 33249552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
    De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
    Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
    Nijs M; Wajs E; Aluisio L; Turkoz I; Daly E; Janik A; Borentain S; Singh JB; DiBernardo A; Wiegand F
    Int J Neuropsychopharmacol; 2020 Jul; 23(7):426-433. PubMed ID: 32270176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).
    Martinotti G; Vita A; Fagiolini A; Maina G; Bertolino A; Dell'Osso B; Siracusano A; Clerici M; Bellomo A; Sani G; d'Andrea G; Chiaie RD; Conca A; Barlati S; Di Lorenzo G; De Fazio P; De Filippis S; Nicolò G; Rosso G; Valchera A; Nucifora D; Di Mauro S; Bassetti R; Martiadis V; Olivola M; Belletti S; Andriola I; Di Nicola M; Pettorruso M; McIntyre RS; di Giannantonio M;
    J Affect Disord; 2022 Dec; 319():646-654. PubMed ID: 36167246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single arketamine in treatment resistant depression: Presentation of 3 cases with regard to sick-leave duration.
    Włodarczyk A; Słupski J; Szarmach J; Cubała WJ
    Asian J Psychiatr; 2024 Jun; 96():104016. PubMed ID: 38554563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB; Fedgchin M; Daly EJ; Drevets WC
    Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
    Gastaldon C; Papola D; Ostuzzi G; Barbui C
    Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
    Doty RL; Popova V; Wylie C; Fedgchin M; Daly E; Janik A; Ochs-Ross R; Lane R; Lim P; Cooper K; Melkote R; Jamieson C; Singh J; Drevets WC
    CNS Drugs; 2021 Jul; 35(7):781-794. PubMed ID: 34235612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Esketamine for treatment resistant depression.
    Swainson J; Thomas RK; Archer S; Chrenek C; MacKay MA; Baker G; Dursun S; Klassen LJ; Chokka P; Demas ML
    Expert Rev Neurother; 2019 Oct; 19(10):899-911. PubMed ID: 31282772
    [No Abstract]   [Full Text] [Related]  

  • 35. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.
    Turkoz I; Nelson JC; Wilkinson ST; Borentain S; Macaluso M; Trivedi MH; Williamson D; Sheehan JJ; Salvadore G; Singh J; Daly E
    Psychiatry Res; 2023 May; 323():115165. PubMed ID: 37019044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.
    Harding L; Zhdanava M; Shah A; Pesa J; Totev TI; Tardif-Samson A; Pilon D; Joshi K
    Curr Med Res Opin; 2024 Sep; 40(9):1615-1623. PubMed ID: 39034772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review.
    Sapkota A; Khurshid H; Qureshi IA; Jahan N; Went TR; Sultan W; Alfonso M
    Cureus; 2021 Aug; 13(8):e17352. PubMed ID: 34447651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J; Kawalec P; Pilc A
    Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
    [No Abstract]   [Full Text] [Related]  

  • 39. Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.
    Teeple A; Zhdanava M; Pilon D; Caron-Lapointe G; Lefebvre P; Joshi K
    Curr Med Res Opin; 2023 Aug; 39(8):1167-1174. PubMed ID: 37492015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
    Kasper S; Cubała WJ; Fagiolini A; Ramos-Quiroga JA; Souery D; Young AH
    World J Biol Psychiatry; 2021 Jul; 22(6):468-482. PubMed ID: 33138665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.